Company: RGNT
Filing Date: 2025-05-19
Form Type: F-1/A
Source: 0001213900-25-045479
Chunk: 96

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-19
Form: F-1/A
Chunk 96
---
 | our ability to obtain market acceptance of our Gelrin hydrogel platform and any future product candidates from the medical community and third-party payors; |

| ● | our plans relating to the further development of our future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; |

| ● | the need to hire additional personnel and our ability to attract and retain such personnel; |

| ● | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |

| ● | our dependence on third parties; |

| ● | our financial performance and our ability to repay our loans and debts; |

| ● | the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; |

| ● | our ability to generate revenue and profit margin under our anticipated contracts which is subject to certain risks; |

| ● | difficulties in our and our partners’ ability to recruit and retain qualified physicians and other healthcare professionals, and enforce our non-compete agreements with our physicians; |

<div align='center'>56</div>

| ● | our ability to restructure our operations to comply with future changes in government regulation; |

| ● | our ability to address any competing technological and market developments that impact our Gelrin hydrogel platform and any future product candidates or their prospective usage by medical professionals; |

| ● | our ability to negotiate favorable terms in any collaboration, licensing or other arrangements into which we may enter and perform our obligations under such collaborations; |

| ● | our ability to maintain, protect and expand our portfolio of intellectual property rights, including patents, patent applications, trade secrets and know-how; |
| ● | our expectations regarding                                                                                                                                     
 having our Ordinary Shares listed on the NYSE American;                                                                                                        |

| ● | our anticipated use of the net proceeds from this offering; and |

| ● | statements as to the impact of the political and security situation in Israel on our business, including due to war or conflicts between Israel, Hamas, Hezbollah, and on other fronts from various extremist groups in the region, such as the Houthis in Yemen and various rebel militia groups in Syria and Iraq. |

Forward-looking statements
are based on our management’s current expectations, estimates, forecasts and projections about our